What is Gilead Sciences, Inc. (GILD.TO)?

Gilead Sciences, Inc. (GILD.TO) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

Gilead Sciences, Inc. (GILD.TO)

Stock analysis · TSX · Healthcare · Drug Manufacturers - General

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.82

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Gilead Sciences, Inc. (GILD.TO) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in…